OBJECTIVES: We aimed to evaluate the significance of microscopic residual disease at the bronchial resection margin (R1-BRM) after curative surgery for non-small cell lung cancer (NSCLC).
INTRODUCTION
Macroscopic and microscopic complete resection (R0-resection) is the most important goal of curative surgery for non-small-cell lung cancer (NSCLC). Despite improvements in preoperative diagnostics to evaluate tumour spreading, microscopic residual disease (R1-resection) at the bronchial resection margin (BRM) occurs in 1.2-17% of all pulmonary resection cases [1] .
When R1-resection at the BRM is reported upon intraoperative histology using frozen sections, surgeons occasionally face a difficult situation in determining whether to proceed with further resection, as anatomical and/or functional limitations may hinder its feasibility. Resection of remnant bronchus with or without adjacent pulmonary parenchyma should be considered to achieve R0-resection since residual disease at the BRM requires adjuvant postoperative treatment and is associated with recurrence and shorter survival. However, specific guidelines have not been clearly established for cases of R1-BRM during curative surgery for NSCLC.
In this context, we aimed to review our experiences with R1-BRM and assess the prognostic significance of microscopic residual disease at the BRM (R1-BRM) after curative surgery for NSCLC.
MATERIALS AND METHODS

Patients
The medical records of patients who underwent curative resection for NSCLC at a single tertiary referral centre between 1994 and 2012 were reviewed. Patients who underwent sublobar resection (segmentectomy or wedge resection); patients with T1, N3 or M1 disease; patients with R1 residual disease other than bronchial stump and patients with R2 residual disease were excluded. T1N0M0 disease was excluded since T1 tumours are surrounded by lung or visceral pleura, without bronchoscopic evidence of invasion more proximal than the lobar bronchus by definition. Thus, we determined that T1N0M0 would not be a good candidate for comparing microscopic residual disease at the BRM after lobectomy/bilobectomy/pneumonectomy for NSCLC.
Among 1800 patients included, 60 (3.3%) patients had pathologically demonstrated microscopic residual disease (R1-resection) at the BRM, and 1740 patients were confirmed to be free of tumour (R0-resection) at the BRM. Assessment of frozen sections of BRM was routinely carried out during each surgery. In cases of microscopic tumour infiltration at BRMs, efforts to reach a complete tumour-free situation (R0-resection) were made through further resection depending on its technical and functional feasibility. However, adjuvant radiation therapy for R1-BRM, rather than reoperation, was selected in cases where further resection was impossible due to poor pulmonary function or anatomical problems or when R1-BRM was discovered postoperatively upon permanent pathological reports. In addition to tumour resection, systematic lymph node dissection was routinely performed.
Data, including age, gender, histological tumour type, pathological TNM staging, pre-and postoperative treatment, and extent of resection, were compared to evaluate the outcome of BRM R1-resection in terms of recurrence and survival after curative surgery. The study was approved by our institutional Ethics Committee/Review Board, which waived the requirement for informed patient consent because of the retrospective nature of the study.
Definitions
All of the R1-resected tissue sections of bronchial stump were reviewed by one pathologist. Patients with R1-resection at the BRM were classified into four different groups based on the exact anatomical site of the residual disease: (i) disease limited to epithelium [carcinoma in situ (CIS)], (ii) submucosal invasion, (iii) peribronchial invasion and (iv) lymphatic infiltration [2] . For statistical comparisons, all patients were reclassified into three groups based on the status of the BRM: R0-resection at the BRM (R0-BRM), residual CIS at the BRM (R1-CIS) and extramucosal residual disease at the BRM (R1-EMD).
The lung cancer pathological staging was based on the seventh edition of the American Joint Committee on Cancer (AJCC) staging manual. Recurrence was categorized as no recurrence, local recurrence, distant recurrence or distant recurrence combined with local recurrence. Local recurrence was defined as recurrence at the stump site, ipsilateral mediastinal lymph nodes or implantation recurrence of the chest wall.
Statistics
Categorical variables are presented as frequencies and percentages, and were analysed using χ 2 test (Fisher's exact test) or linear-by-linear association test. Continuous variables are expressed as mean ± standard deviation or median with ranges and the Kruskal-Wallis test was used for comparison. Cumulative incidence rates for individual and composite outcomes were drawn by the Kaplan-Meier method, and the log-rank test was used for comparison. Multivariable analyses using the Cox proportional hazard regression model were carried out. The results thereof are expressed as hazard ratios (HRs) with 95% confidence intervals (CIs). All reported P-values are two-sided, and P < 0.05 was considered statistically significant. Analyses were performed using the SPSS software version 18.0 (IBM Corporation, Somer, NY, USA).
RESULTS
Baseline characteristics of patients
Among the 1800 patients included in the study, R0-resection at the BRM (R0-BRM) was achieved in 1740 patients, and R1-resection at the BRM (R1-BRM) was confirmed in 60 patients. R1-BRM consisted of 18 cases (1.0%) of mucosal CIS, 19 cases (1.1%) of submucosal invasion, 5 cases (0.3%) of lymphatic invasion and 18 cases (1.0%) of peribronchial invasion. Based on the status of the BRM, 1740 patients were classified as R0-BRM, 18 as R1-CIS and 42 as R1-EMD. The baseline characteristics of these groups are given in Table 1 .
Recurrence
Of the 1800 patients, 673 patients were diagnosed with recurrence during the study period. The freedom-from-overall recurrence rate was 55.9% at Year 5 and 49.7% at Year 10. The differences of overall recurrence between groups were not significant (R0 versus R1-CIS, P = 0.27; R0 versus R1-EMD, P = 0.55, Fig. 1A ).
Stump site recurrence was diagnosed in 43 patients during the study period. Among the 43 patients diagnosed with stump recurrence, 38 patients were in the R0 group, 2 patients were in the R1-CIS group and 3 patients were in the R1-EMD group. The 5-year cumulative incidences of stump recurrence in group R0, R1-CIS and R1-EMD were 3.1, 5.6, and 12.2%, respectively. Significant differences in stump site recurrence were observed between the groups (R0 versus R1-CIS, P = 0.008; R0 versus R1-EMD, P = 0.007, Fig. 1B ).
Overall survival
Survival data were completed in 1797 (99.8%) patients with a mean follow-up duration of 53.4 ± 40.9 months. There were 854 deaths (47.4%) during the study period. The overall survival rate was 57.1% at Year 5 and 40.0% at Year 10. The 5-year survival rates of patients with Stage IB, Stage II and Stage IIIA diseases were 72.6, 55.0 and 39.6%, respectively (P < 0.001).
In patients with Stage IB or II disease, the overall survival rate of the R1-EMD group was significantly lower than that of the R0 group (P = 0.014), whereas the difference in overall survival between the R1-CIS group and the R0 group was not significant (P = 0.37, Fig. 2A ). In the multivariate analysis of 1200 patients with Stage IB or II disease who had not received preoperative therapies showed that age (HR, 1.037; 95% CI, 1.026-1.049; P < 0.001), male sex (versus female; HR, 1.560; 95% CI, 1.200-2.028; P = 0.001), pneumonectomy (versus lobectomy; HR, 1.504; 95% CI, 1.164-1.944; P = 0.002) and R1-EMD (versus R0-BRM; HR, 2.214; 95% CI, 1.132-4.331; P = 0.020) were independent predictors for overall survival (Table 2) .
In Stage IIIA disease, the overall survival rates of the R1-CIS group (P = 0.87) and R1-EMD group (P = 0.45) were not significantly different from that of the R0-BRM group (Fig. 2B) . In the multivariate analysis of 483 patients who had not received preoperative therapies, age (HR, 1.018; 95% CI, 1.006-1.031; P = 0.004), male sex (HR, 1.432; 95% CI, 1.049-1.955; P = 0.024) and postoperative treatment (HR, 0.502; 95% CI, 0.375-0.672; P < 0.001) were independent predictors for overall survival (Table 2) .
DISCUSSION
Despite the progress of techniques in the preoperative evaluation for lung cancer, such as high-resolution computed tomography and bronchoscopy, positive BRMs are observed, with 1.1-17% of cases having residual tumour at the BRM. Anatomical and functional limitations are mentioned as the possible causes of incomplete resection in 40% of the cases according to a previous study [3] . Another cause of R1-resection at the BRM is lack of detection of tumour infiltration during the operation because of false-negative intraoperative histology [4] . Microscopic residual tumour (R1-resection) at the BRM is classified into different patterns [2, 3, [5] [6] [7] [8] [9] , and a recent review described the classification of positive margin of resected bronchus on behalf of the International Association for the Study of Lung Cancer (IASLC) International Staging Committee as follows: (i) inner bronchial wall, either mucosal CIS or invasion of submucosal tissues; (ii) outer bronchial wall, either primary tumour or invasion from nearby metastatic tumour into lymph nodes; (iii) invasion in the submucosal or peribronchial lymphatics; and (iv) detached floating fragments of tumour within the bronchial lumen from intraluminal polypoid tumours without attachment at the margin [9] . We classified R1-positive BRM on the basis of these criteria; however, we divided patients into three groups for statistical analysis: R0, R1-CIS and R1-EMD. This division of R1-BRM was made in an attempt to subdivide the cases into clinically meaningful subgroups. With regard to recurrence, limited data on the incidence or treatment of R1-BRM are available. The present study focused on stump recurrence rather than local or distant recurrence. Results demonstrated that the 5-year cumulative rate of stump recurrence was 5.6% in the R1-CIS group and 12.2% in the R1-EMD group. The stump recurrence rates of these two groups were significantly higher than that of the R0-BRM group. These results indicate that complete resection of the bronchial stump is definitely important to improve disease-free survival.
The presence of CIS at the BRM is rare, especially in lung cancer cases other than squamous cell carcinoma [10] . Our results demonstrated that the incidence of CIS at the BRM was 1.0%, and that 88.9% of CIS cases were squamous cell carcinomas, which is consistent with previous studies. As a result of previous studies, the concept of field carcinogenesis, the concept of a gradual and stepwise progression from early epithelial changes to metaplasia, mild, moderate and severe dysplasia, and finally CIS and the concept of microinvasive bronchial carcinoma have developed [11] [12] [13] . By the current standards, squamous dysplasia in the bronchial mucosa is not regarded as a positive margin, but CIS is regarded as a R1-resection; however, whether CIS should be considered as R1-resection is a matter of debate since the presence of CIS does not seem to negatively affect prognosis after resection [9] . The results obtained in our survey indicate that R1-CIS should be considered as R1-resection rather than R0-resection, because the stump recurrence rate of R1-CIS was significantly higher than that of R0-BRM, although the overall survival was not affected by R1-CIS.
We analysed survival based on the extent of residual disease at the BRM and on stage (Stage IB or II versus Stage IIIA). KaplanMeier curves and log-rank tests showed that in patients with Stage IB or II disease, the presence of R1-EMD at the BRM had an adverse effect on survival, although mucosal CIS had a similar prognosis to R0-BRM. Further, R1-CIS and R1-EMD did not have a poorer prognosis than R0-BRM in Stage IIIA disease. These results are consistent with the previous studies that reported that the survival of patients with Stage I and II NSCLC and R1-BRM was significantly worse than the stage-corrected survival after R0-resection, and that the negative effect of microscopic residual disease at the BRM in Stage III NSCLC is less pronounced [2, 3, [14] [15] [16] [17] . We postulate that the survival of patients with Stage IB and II disease is limited by local recurrence, including stump recurrence, whereas patients with Stage III disease probably die from disseminated disease rather than local recurrence. Multivariate analysis of overall survival also indicated that R1-EMD was an independent risk factor in Stage IB or II disease but not in Stage IIIA disease.
The implication of these results for decision-making during curative surgery is that further resection to achieve R0-BRM should be considered when intraoperative frozen section reveals positive R1-EMD in Stage IB or II disease. However, further resection in the R1-BRM may further reduce pulmonary function, which is unsuitable for patients with poor pulmonary reserve or other major comorbidity. When further resection of bronchial stump can be considered, parenchyma-saving bronchial resection such as wedge-bronchoplasty or sleeve resection should be preferred to pneumonectomy since pneumonectomy itself was an independent risk factor of overall survival in Stage IB and II diseases in the present study. Moreover, we believe that it is not necessary to perform pneumonectomy for R0-resection in cases of R1-CIS at the BRM, because R1-CIS was not a negative predictor of overall survival in Stage IB or II disease. In Stage IIIA disease, however, a more conservative surgical strategy could be considered. It is more important for improving overall survival to perform adjuvant therapies rather than to achieve R0-BRM with further resection in Stage IIIA disease.
This study has important limitations, stemming from the small population, retrospective design and single-centre experience. Furthermore, preoperative pathological evaluation using mediastinoscopy or endobronchial ultrasound-guided fine-needle aspiration biopsy (EBUS-FNAB) and intraoperative frozen section evaluation seems to be important to make decisions; however, EBUS-FNAB and intraoperative frozen section of mediastinal lymph nodes has its own limitation. Future studies are required to validate the results of this study in a larger population.
In conclusion, R1-BRM exhibits a higher rate of stump recurrence, compared with that of R0-BRM. R1-EMD was also associated with poor overall survival in Stage IB/II disease. In Stage IIIA disease, R1-BRM showed similar overall survival to that for R0-BRM, although, in the present study, the number of patients was too small to draw definitive conclusions thereon.
